Testing hydronidone capsules in healthy volunteers
Treatments studied
Part of Digestive system clinical trials.
This trial tests a new medicine called Hydronidone Capsule in healthy people to see how the body processes it and whether it is safe. If you are in good health, you may be able to join this first-in-human study.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 45 years old.
- You are generally healthy, with no major medical conditions.
- You have a body mass index (BMI) between 19 and 26, and weigh at least 50 kg (men) or 45 kg (women).
- You have not taken any prescription or over-the-counter medications (including herbal supplements) in the last 14 days.
- You do not smoke more than 5 cigarettes per day and can avoid tobacco during the trial.
- You have not participated in another clinical trial in the last 3 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 3 study tests whether hydronidone capsules can help people with long-term hepatitis B–related liver scarring (fibrosis). It aims to track whether treatment reduces or delays serious liver complications over time.
This trial tests a long-term treatment called hydronidone for liver scarring (fibrosis) caused by chronic hepatitis B. It aims to see if the treatment can help slow or reverse liver damage in people who are already on antiviral therapy or starting treatment for the first time.
This study tests how a drug called hydronidone is processed and removed from the body using a very small amount of radioactive labeling. It helps researchers understand how the drug works, so it may lead to better treatments for conditions like liver fibrosis.
This trial tests a single dose of the study drug hydroxynidone in people with different levels of kidney function, including healthy volunteers and those with kidney disease. The goal is to learn how the drug works in the body when kidneys are not working normally.
This trial studies how a new drug (HRS-9813) interacts with two existing lung fibrosis drugs (pirfenidone and nintedanib) in healthy adults. The results will help doctors understand how to combine these medicines safely.
This study tests a new oral medication, HY8931, in healthy adults to see if it is safe and how the body processes it. You will be closely monitored during the trial.
Hear when a new Liver Fibrosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.